Global Generic Drugs

Generic Drugs Comprehensive Study by Type (Simple Generic Drugs, Super Generic Drugs, Biosimilars), Application (Respiratory Products, Anti-Infective Drugs, Central Nervous System Drugs, Cardiovascular Products, Anti-Arthritis Drugs, Anti-Cancer Drugs, Other), Sales Channel (Sales Channel Hospital Pharmacies, Drug Stores, Retail Pharmacies, Online Channels), Drug Delivery (Oral, Injectables, Dermal/Topical, Inhalers) Players and Region - Global Market Outlook to 2030

Generic Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Generic Drugs Market Scope
Generic Drugs are referred to as a drug product that is comparable to a brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended use. These drugs have the same active ingredients, dosage form, strength, route of administration, and conditions of use as original branded products but with lower prices. Generic drugs help to reduce drug costs and increase drug use. According to the Association for Accessible Medicines, 89% of all prescriptions dispensed in the United States are filled with a generic drug. North America region is the largest supplier of generic drugs, following Europe is the second-largest supplier of generic drugs. Of the Asian countries, India is emerging as a leading country for the generic drugs market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledTeva Pharmaceutical Industries, Ltd. (Israel), Dr. Reddy’s Laboratories (India), Sandoz International GmbH (Germany), Apotex, Inc. (Canada), Par Pharmaceutical, Inc. (United States), Hospira, Inc. (United States), Watson Pharmaceuticals, Ltd. (India), Novartis (Switzerland), Fresenius SE & Co. KGaA (Germany), Pfizer (United States), Sun Pharmaceutical Industries (India), Ranbaxy Laboratories, Ltd (India), Actavis (Ireland), Mylan, Inc. (United States), Cipla (India) and Amneal Pharmaceuticals (United States)
CAGR5.7%


Key players are adopting numerous strategies to gain market attention and to increase their market share, this strategy can be listed as increasing product portfolio, making partnerships to adopt certain technologies, and acquiring small players to finish the competition in the future. As well as investing money in the R&D sector to make technical upgrades to the product. Research Analyst at AMA estimates that United States, Europe, China and Indian Players will contribute to the maximum growth of Global Generic Drugs market throughout the predicted period.

Teva Pharmaceutical Industries, Ltd. (Israel), Dr. Reddy’s Laboratories (India), Sandoz International GmbH (Germany), Apotex, Inc. (Canada), Par Pharmaceutical, Inc. (United States), Hospira, Inc. (United States), Watson Pharmaceuticals, Ltd. (India), Novartis (Switzerland), Fresenius SE & Co. KGaA (Germany), Pfizer (United States), Sun Pharmaceutical Industries (India), Ranbaxy Laboratories, Ltd (India), Actavis (Ireland), Mylan, Inc. (United States), Cipla (India) and Amneal Pharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Aurobindo Pharma Limited (India), Aspen Pharmacare Holdings Limited (South Africa), Lupin Limited (India) and Zydus Cadila (India).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Generic Drugs market by Type , by Application (Respiratory Products, Anti-Infective Drugs, Central Nervous System Drugs, Cardiovascular Products, Anti-Arthritis Drugs, Anti-Cancer Drugs and Other) and Region with country level break-up.

On the basis of geography, the market of Generic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies

In January 2023, Hikma and Boehringer Ingelheim formed a strategic partnership in the MENA region. This partnership focuses on co-promotion, distribution, and potential co-development of select branded and generic products in the Middle East and North Africa.


Influencing Trend:
Advent of Robotic Process Automation (RPA)

Market Growth Drivers:
Increasing Demand for Generic Drugs in Emerging Countries such as China and India, Cost-Benefit compared to the Branded Drugs and Large Number of Patent Expired Branded Drugs

Challenges:
Presence of Local Players

Restraints:
Stringent Governmental Regulations and Adverse Effects Associated With Generic Drugs

Opportunities:
Government Promoting the Pharmaceutical Sector and Increasing Use of Hospital-owned Generics

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Generic Drugs Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry

Report Objectives / Segmentation Covered

By Type
  • Simple Generic Drugs
  • Super Generic Drugs
  • Biosimilars
By Application
  • Respiratory Products
  • Anti-Infective Drugs
  • Central Nervous System Drugs
  • Cardiovascular Products
  • Anti-Arthritis Drugs
  • Anti-Cancer Drugs
  • Other
By Sales Channel
  • Sales Channel Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Channels

By Drug Delivery
  • Oral
  • Injectables
  • Dermal/Topical
  • Inhalers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand for Generic Drugs in Emerging Countries such as China and India
      • 3.2.2. Cost-Benefit compared to the Branded Drugs
      • 3.2.3. Large Number of Patent Expired Branded Drugs
    • 3.3. Market Challenges
      • 3.3.1. Presence of Local Players
    • 3.4. Market Trends
      • 3.4.1. Advent of Robotic Process Automation (RPA)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Generic Drugs, by Type, Application, Sales Channel, Drug Delivery and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Generic Drugs (Value)
      • 5.2.1. Global Generic Drugs by: Type (Value)
        • 5.2.1.1. Simple Generic Drugs
        • 5.2.1.2. Super Generic Drugs
        • 5.2.1.3. Biosimilars
      • 5.2.2. Global Generic Drugs by: Application (Value)
        • 5.2.2.1. Respiratory Products
        • 5.2.2.2. Anti-Infective Drugs
        • 5.2.2.3. Central Nervous System Drugs
        • 5.2.2.4. Cardiovascular Products
        • 5.2.2.5. Anti-Arthritis Drugs
        • 5.2.2.6. Anti-Cancer Drugs
        • 5.2.2.7. Other
      • 5.2.3. Global Generic Drugs by: Sales Channel (Value)
        • 5.2.3.1. Sales Channel Hospital Pharmacies
        • 5.2.3.2. Drug Stores
        • 5.2.3.3. Retail Pharmacies
        • 5.2.3.4. Online Channels
      • 5.2.4. Global Generic Drugs by: Drug Delivery (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Injectables
        • 5.2.4.3. Dermal/Topical
        • 5.2.4.4. Inhalers
      • 5.2.5. Global Generic Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Generic Drugs (Price)
      • 5.3.1. Global Generic Drugs by: Type (Price)
  • 6. Generic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Industries, Ltd. (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Dr. Reddy’s Laboratories (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sandoz International GmbH (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Apotex, Inc. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Par Pharmaceutical, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hospira, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Watson Pharmaceuticals, Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Fresenius SE & Co. KGaA (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sun Pharmaceutical Industries (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Ranbaxy Laboratories, Ltd (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Actavis (Ireland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Mylan, Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Cipla (India)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Amneal Pharmaceuticals (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Generic Drugs Sale, by Type, Application, Sales Channel, Drug Delivery and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Generic Drugs (Value)
      • 7.2.1. Global Generic Drugs by: Type (Value)
        • 7.2.1.1. Simple Generic Drugs
        • 7.2.1.2. Super Generic Drugs
        • 7.2.1.3. Biosimilars
      • 7.2.2. Global Generic Drugs by: Application (Value)
        • 7.2.2.1. Respiratory Products
        • 7.2.2.2. Anti-Infective Drugs
        • 7.2.2.3. Central Nervous System Drugs
        • 7.2.2.4. Cardiovascular Products
        • 7.2.2.5. Anti-Arthritis Drugs
        • 7.2.2.6. Anti-Cancer Drugs
        • 7.2.2.7. Other
      • 7.2.3. Global Generic Drugs by: Sales Channel (Value)
        • 7.2.3.1. Sales Channel Hospital Pharmacies
        • 7.2.3.2. Drug Stores
        • 7.2.3.3. Retail Pharmacies
        • 7.2.3.4. Online Channels
      • 7.2.4. Global Generic Drugs by: Drug Delivery (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Injectables
        • 7.2.4.3. Dermal/Topical
        • 7.2.4.4. Inhalers
      • 7.2.5. Global Generic Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Generic Drugs (Price)
      • 7.3.1. Global Generic Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Generic Drugs: by Type(USD Million)
  • Table 2. Generic Drugs Simple Generic Drugs , by Region USD Million (2018-2023)
  • Table 3. Generic Drugs Super Generic Drugs , by Region USD Million (2018-2023)
  • Table 4. Generic Drugs Biosimilars , by Region USD Million (2018-2023)
  • Table 5. Generic Drugs: by Application(USD Million)
  • Table 6. Generic Drugs Respiratory Products , by Region USD Million (2018-2023)
  • Table 7. Generic Drugs Anti-Infective Drugs , by Region USD Million (2018-2023)
  • Table 8. Generic Drugs Central Nervous System Drugs , by Region USD Million (2018-2023)
  • Table 9. Generic Drugs Cardiovascular Products , by Region USD Million (2018-2023)
  • Table 10. Generic Drugs Anti-Arthritis Drugs , by Region USD Million (2018-2023)
  • Table 11. Generic Drugs Anti-Cancer Drugs , by Region USD Million (2018-2023)
  • Table 12. Generic Drugs Other , by Region USD Million (2018-2023)
  • Table 13. Generic Drugs: by Sales Channel(USD Million)
  • Table 14. Generic Drugs Sales Channel Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 15. Generic Drugs Drug Stores , by Region USD Million (2018-2023)
  • Table 16. Generic Drugs Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 17. Generic Drugs Online Channels , by Region USD Million (2018-2023)
  • Table 18. Generic Drugs: by Drug Delivery(USD Million)
  • Table 19. Generic Drugs Oral , by Region USD Million (2018-2023)
  • Table 20. Generic Drugs Injectables , by Region USD Million (2018-2023)
  • Table 21. Generic Drugs Dermal/Topical , by Region USD Million (2018-2023)
  • Table 22. Generic Drugs Inhalers , by Region USD Million (2018-2023)
  • Table 23. South America Generic Drugs, by Country USD Million (2018-2023)
  • Table 24. South America Generic Drugs, by Type USD Million (2018-2023)
  • Table 25. South America Generic Drugs, by Application USD Million (2018-2023)
  • Table 26. South America Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 27. South America Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 28. Brazil Generic Drugs, by Type USD Million (2018-2023)
  • Table 29. Brazil Generic Drugs, by Application USD Million (2018-2023)
  • Table 30. Brazil Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 31. Brazil Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 32. Argentina Generic Drugs, by Type USD Million (2018-2023)
  • Table 33. Argentina Generic Drugs, by Application USD Million (2018-2023)
  • Table 34. Argentina Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 35. Argentina Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 36. Rest of South America Generic Drugs, by Type USD Million (2018-2023)
  • Table 37. Rest of South America Generic Drugs, by Application USD Million (2018-2023)
  • Table 38. Rest of South America Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 39. Rest of South America Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 40. Asia Pacific Generic Drugs, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Generic Drugs, by Type USD Million (2018-2023)
  • Table 42. Asia Pacific Generic Drugs, by Application USD Million (2018-2023)
  • Table 43. Asia Pacific Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 44. Asia Pacific Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 45. China Generic Drugs, by Type USD Million (2018-2023)
  • Table 46. China Generic Drugs, by Application USD Million (2018-2023)
  • Table 47. China Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 48. China Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 49. Japan Generic Drugs, by Type USD Million (2018-2023)
  • Table 50. Japan Generic Drugs, by Application USD Million (2018-2023)
  • Table 51. Japan Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 52. Japan Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 53. India Generic Drugs, by Type USD Million (2018-2023)
  • Table 54. India Generic Drugs, by Application USD Million (2018-2023)
  • Table 55. India Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 56. India Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 57. South Korea Generic Drugs, by Type USD Million (2018-2023)
  • Table 58. South Korea Generic Drugs, by Application USD Million (2018-2023)
  • Table 59. South Korea Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 60. South Korea Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 61. Taiwan Generic Drugs, by Type USD Million (2018-2023)
  • Table 62. Taiwan Generic Drugs, by Application USD Million (2018-2023)
  • Table 63. Taiwan Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 64. Taiwan Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 65. Australia Generic Drugs, by Type USD Million (2018-2023)
  • Table 66. Australia Generic Drugs, by Application USD Million (2018-2023)
  • Table 67. Australia Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 68. Australia Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Generic Drugs, by Type USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Generic Drugs, by Application USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 73. Europe Generic Drugs, by Country USD Million (2018-2023)
  • Table 74. Europe Generic Drugs, by Type USD Million (2018-2023)
  • Table 75. Europe Generic Drugs, by Application USD Million (2018-2023)
  • Table 76. Europe Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 77. Europe Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 78. Germany Generic Drugs, by Type USD Million (2018-2023)
  • Table 79. Germany Generic Drugs, by Application USD Million (2018-2023)
  • Table 80. Germany Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 81. Germany Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 82. France Generic Drugs, by Type USD Million (2018-2023)
  • Table 83. France Generic Drugs, by Application USD Million (2018-2023)
  • Table 84. France Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 85. France Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 86. Italy Generic Drugs, by Type USD Million (2018-2023)
  • Table 87. Italy Generic Drugs, by Application USD Million (2018-2023)
  • Table 88. Italy Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 89. Italy Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 90. United Kingdom Generic Drugs, by Type USD Million (2018-2023)
  • Table 91. United Kingdom Generic Drugs, by Application USD Million (2018-2023)
  • Table 92. United Kingdom Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 93. United Kingdom Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 94. Netherlands Generic Drugs, by Type USD Million (2018-2023)
  • Table 95. Netherlands Generic Drugs, by Application USD Million (2018-2023)
  • Table 96. Netherlands Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 97. Netherlands Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 98. Rest of Europe Generic Drugs, by Type USD Million (2018-2023)
  • Table 99. Rest of Europe Generic Drugs, by Application USD Million (2018-2023)
  • Table 100. Rest of Europe Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 101. Rest of Europe Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 102. MEA Generic Drugs, by Country USD Million (2018-2023)
  • Table 103. MEA Generic Drugs, by Type USD Million (2018-2023)
  • Table 104. MEA Generic Drugs, by Application USD Million (2018-2023)
  • Table 105. MEA Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 106. MEA Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 107. Middle East Generic Drugs, by Type USD Million (2018-2023)
  • Table 108. Middle East Generic Drugs, by Application USD Million (2018-2023)
  • Table 109. Middle East Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 110. Middle East Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 111. Africa Generic Drugs, by Type USD Million (2018-2023)
  • Table 112. Africa Generic Drugs, by Application USD Million (2018-2023)
  • Table 113. Africa Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 114. Africa Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 115. North America Generic Drugs, by Country USD Million (2018-2023)
  • Table 116. North America Generic Drugs, by Type USD Million (2018-2023)
  • Table 117. North America Generic Drugs, by Application USD Million (2018-2023)
  • Table 118. North America Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 119. North America Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 120. United States Generic Drugs, by Type USD Million (2018-2023)
  • Table 121. United States Generic Drugs, by Application USD Million (2018-2023)
  • Table 122. United States Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 123. United States Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 124. Canada Generic Drugs, by Type USD Million (2018-2023)
  • Table 125. Canada Generic Drugs, by Application USD Million (2018-2023)
  • Table 126. Canada Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 127. Canada Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 128. Mexico Generic Drugs, by Type USD Million (2018-2023)
  • Table 129. Mexico Generic Drugs, by Application USD Million (2018-2023)
  • Table 130. Mexico Generic Drugs, by Sales Channel USD Million (2018-2023)
  • Table 131. Mexico Generic Drugs, by Drug Delivery USD Million (2018-2023)
  • Table 132. Generic Drugs: by Type(USD/Units)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Generic Drugs: by Type(USD Million)
  • Table 150. Generic Drugs Simple Generic Drugs , by Region USD Million (2025-2030)
  • Table 151. Generic Drugs Super Generic Drugs , by Region USD Million (2025-2030)
  • Table 152. Generic Drugs Biosimilars , by Region USD Million (2025-2030)
  • Table 153. Generic Drugs: by Application(USD Million)
  • Table 154. Generic Drugs Respiratory Products , by Region USD Million (2025-2030)
  • Table 155. Generic Drugs Anti-Infective Drugs , by Region USD Million (2025-2030)
  • Table 156. Generic Drugs Central Nervous System Drugs , by Region USD Million (2025-2030)
  • Table 157. Generic Drugs Cardiovascular Products , by Region USD Million (2025-2030)
  • Table 158. Generic Drugs Anti-Arthritis Drugs , by Region USD Million (2025-2030)
  • Table 159. Generic Drugs Anti-Cancer Drugs , by Region USD Million (2025-2030)
  • Table 160. Generic Drugs Other , by Region USD Million (2025-2030)
  • Table 161. Generic Drugs: by Sales Channel(USD Million)
  • Table 162. Generic Drugs Sales Channel Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 163. Generic Drugs Drug Stores , by Region USD Million (2025-2030)
  • Table 164. Generic Drugs Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 165. Generic Drugs Online Channels , by Region USD Million (2025-2030)
  • Table 166. Generic Drugs: by Drug Delivery(USD Million)
  • Table 167. Generic Drugs Oral , by Region USD Million (2025-2030)
  • Table 168. Generic Drugs Injectables , by Region USD Million (2025-2030)
  • Table 169. Generic Drugs Dermal/Topical , by Region USD Million (2025-2030)
  • Table 170. Generic Drugs Inhalers , by Region USD Million (2025-2030)
  • Table 171. South America Generic Drugs, by Country USD Million (2025-2030)
  • Table 172. South America Generic Drugs, by Type USD Million (2025-2030)
  • Table 173. South America Generic Drugs, by Application USD Million (2025-2030)
  • Table 174. South America Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 175. South America Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 176. Brazil Generic Drugs, by Type USD Million (2025-2030)
  • Table 177. Brazil Generic Drugs, by Application USD Million (2025-2030)
  • Table 178. Brazil Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 179. Brazil Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 180. Argentina Generic Drugs, by Type USD Million (2025-2030)
  • Table 181. Argentina Generic Drugs, by Application USD Million (2025-2030)
  • Table 182. Argentina Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 183. Argentina Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 184. Rest of South America Generic Drugs, by Type USD Million (2025-2030)
  • Table 185. Rest of South America Generic Drugs, by Application USD Million (2025-2030)
  • Table 186. Rest of South America Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 187. Rest of South America Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 188. Asia Pacific Generic Drugs, by Country USD Million (2025-2030)
  • Table 189. Asia Pacific Generic Drugs, by Type USD Million (2025-2030)
  • Table 190. Asia Pacific Generic Drugs, by Application USD Million (2025-2030)
  • Table 191. Asia Pacific Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 192. Asia Pacific Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 193. China Generic Drugs, by Type USD Million (2025-2030)
  • Table 194. China Generic Drugs, by Application USD Million (2025-2030)
  • Table 195. China Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 196. China Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 197. Japan Generic Drugs, by Type USD Million (2025-2030)
  • Table 198. Japan Generic Drugs, by Application USD Million (2025-2030)
  • Table 199. Japan Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 200. Japan Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 201. India Generic Drugs, by Type USD Million (2025-2030)
  • Table 202. India Generic Drugs, by Application USD Million (2025-2030)
  • Table 203. India Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 204. India Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 205. South Korea Generic Drugs, by Type USD Million (2025-2030)
  • Table 206. South Korea Generic Drugs, by Application USD Million (2025-2030)
  • Table 207. South Korea Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 208. South Korea Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 209. Taiwan Generic Drugs, by Type USD Million (2025-2030)
  • Table 210. Taiwan Generic Drugs, by Application USD Million (2025-2030)
  • Table 211. Taiwan Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 212. Taiwan Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 213. Australia Generic Drugs, by Type USD Million (2025-2030)
  • Table 214. Australia Generic Drugs, by Application USD Million (2025-2030)
  • Table 215. Australia Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 216. Australia Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 217. Rest of Asia-Pacific Generic Drugs, by Type USD Million (2025-2030)
  • Table 218. Rest of Asia-Pacific Generic Drugs, by Application USD Million (2025-2030)
  • Table 219. Rest of Asia-Pacific Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 220. Rest of Asia-Pacific Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 221. Europe Generic Drugs, by Country USD Million (2025-2030)
  • Table 222. Europe Generic Drugs, by Type USD Million (2025-2030)
  • Table 223. Europe Generic Drugs, by Application USD Million (2025-2030)
  • Table 224. Europe Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 225. Europe Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 226. Germany Generic Drugs, by Type USD Million (2025-2030)
  • Table 227. Germany Generic Drugs, by Application USD Million (2025-2030)
  • Table 228. Germany Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 229. Germany Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 230. France Generic Drugs, by Type USD Million (2025-2030)
  • Table 231. France Generic Drugs, by Application USD Million (2025-2030)
  • Table 232. France Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 233. France Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 234. Italy Generic Drugs, by Type USD Million (2025-2030)
  • Table 235. Italy Generic Drugs, by Application USD Million (2025-2030)
  • Table 236. Italy Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 237. Italy Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 238. United Kingdom Generic Drugs, by Type USD Million (2025-2030)
  • Table 239. United Kingdom Generic Drugs, by Application USD Million (2025-2030)
  • Table 240. United Kingdom Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 241. United Kingdom Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 242. Netherlands Generic Drugs, by Type USD Million (2025-2030)
  • Table 243. Netherlands Generic Drugs, by Application USD Million (2025-2030)
  • Table 244. Netherlands Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 245. Netherlands Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 246. Rest of Europe Generic Drugs, by Type USD Million (2025-2030)
  • Table 247. Rest of Europe Generic Drugs, by Application USD Million (2025-2030)
  • Table 248. Rest of Europe Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 249. Rest of Europe Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 250. MEA Generic Drugs, by Country USD Million (2025-2030)
  • Table 251. MEA Generic Drugs, by Type USD Million (2025-2030)
  • Table 252. MEA Generic Drugs, by Application USD Million (2025-2030)
  • Table 253. MEA Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 254. MEA Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 255. Middle East Generic Drugs, by Type USD Million (2025-2030)
  • Table 256. Middle East Generic Drugs, by Application USD Million (2025-2030)
  • Table 257. Middle East Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 258. Middle East Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 259. Africa Generic Drugs, by Type USD Million (2025-2030)
  • Table 260. Africa Generic Drugs, by Application USD Million (2025-2030)
  • Table 261. Africa Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 262. Africa Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 263. North America Generic Drugs, by Country USD Million (2025-2030)
  • Table 264. North America Generic Drugs, by Type USD Million (2025-2030)
  • Table 265. North America Generic Drugs, by Application USD Million (2025-2030)
  • Table 266. North America Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 267. North America Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 268. United States Generic Drugs, by Type USD Million (2025-2030)
  • Table 269. United States Generic Drugs, by Application USD Million (2025-2030)
  • Table 270. United States Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 271. United States Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 272. Canada Generic Drugs, by Type USD Million (2025-2030)
  • Table 273. Canada Generic Drugs, by Application USD Million (2025-2030)
  • Table 274. Canada Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 275. Canada Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 276. Mexico Generic Drugs, by Type USD Million (2025-2030)
  • Table 277. Mexico Generic Drugs, by Application USD Million (2025-2030)
  • Table 278. Mexico Generic Drugs, by Sales Channel USD Million (2025-2030)
  • Table 279. Mexico Generic Drugs, by Drug Delivery USD Million (2025-2030)
  • Table 280. Generic Drugs: by Type(USD/Units)
  • Table 281. Research Programs/Design for This Report
  • Table 282. Key Data Information from Secondary Sources
  • Table 283. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Generic Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Generic Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Generic Drugs: by Sales Channel USD Million (2018-2023)
  • Figure 7. Global Generic Drugs: by Drug Delivery USD Million (2018-2023)
  • Figure 8. South America Generic Drugs Share (%), by Country
  • Figure 9. Asia Pacific Generic Drugs Share (%), by Country
  • Figure 10. Europe Generic Drugs Share (%), by Country
  • Figure 11. MEA Generic Drugs Share (%), by Country
  • Figure 12. North America Generic Drugs Share (%), by Country
  • Figure 13. Global Generic Drugs: by Type USD/Units (2018-2023)
  • Figure 14. Global Generic Drugs share by Players 2023 (%)
  • Figure 15. Global Generic Drugs share by Players (Top 3) 2023(%)
  • Figure 16. Global Generic Drugs share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Teva Pharmaceutical Industries, Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 19. Teva Pharmaceutical Industries, Ltd. (Israel) Revenue: by Geography 2023
  • Figure 20. Dr. Reddy’s Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 21. Dr. Reddy’s Laboratories (India) Revenue: by Geography 2023
  • Figure 22. Sandoz International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Sandoz International GmbH (Germany) Revenue: by Geography 2023
  • Figure 24. Apotex, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 25. Apotex, Inc. (Canada) Revenue: by Geography 2023
  • Figure 26. Par Pharmaceutical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Par Pharmaceutical, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Hospira, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Hospira, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Watson Pharmaceuticals, Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 31. Watson Pharmaceuticals, Ltd. (India) Revenue: by Geography 2023
  • Figure 32. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 34. Fresenius SE & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Fresenius SE & Co. KGaA (Germany) Revenue: by Geography 2023
  • Figure 36. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer (United States) Revenue: by Geography 2023
  • Figure 38. Sun Pharmaceutical Industries (India) Revenue, Net Income and Gross profit
  • Figure 39. Sun Pharmaceutical Industries (India) Revenue: by Geography 2023
  • Figure 40. Ranbaxy Laboratories, Ltd (India) Revenue, Net Income and Gross profit
  • Figure 41. Ranbaxy Laboratories, Ltd (India) Revenue: by Geography 2023
  • Figure 42. Actavis (Ireland) Revenue, Net Income and Gross profit
  • Figure 43. Actavis (Ireland) Revenue: by Geography 2023
  • Figure 44. Mylan, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 45. Mylan, Inc. (United States) Revenue: by Geography 2023
  • Figure 46. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 47. Cipla (India) Revenue: by Geography 2023
  • Figure 48. Amneal Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 49. Amneal Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 50. Global Generic Drugs: by Type USD Million (2025-2030)
  • Figure 51. Global Generic Drugs: by Application USD Million (2025-2030)
  • Figure 52. Global Generic Drugs: by Sales Channel USD Million (2025-2030)
  • Figure 53. Global Generic Drugs: by Drug Delivery USD Million (2025-2030)
  • Figure 54. South America Generic Drugs Share (%), by Country
  • Figure 55. Asia Pacific Generic Drugs Share (%), by Country
  • Figure 56. Europe Generic Drugs Share (%), by Country
  • Figure 57. MEA Generic Drugs Share (%), by Country
  • Figure 58. North America Generic Drugs Share (%), by Country
  • Figure 59. Global Generic Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Teva Pharmaceutical Industries, Ltd. (Israel)
  • Dr. Reddy’s Laboratories (India)
  • Sandoz International GmbH (Germany)
  • Apotex, Inc. (Canada)
  • Par Pharmaceutical, Inc. (United States)
  • Hospira, Inc. (United States)
  • Watson Pharmaceuticals, Ltd. (India)
  • Novartis (Switzerland)
  • Fresenius SE & Co. KGaA (Germany)
  • Pfizer (United States)
  • Sun Pharmaceutical Industries (India)
  • Ranbaxy Laboratories, Ltd (India)
  • Actavis (Ireland)
  • Mylan, Inc. (United States)
  • Cipla (India)
  • Amneal Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Aurobindo Pharma Limited (India) , Aspen Pharmacare Holdings Limited (South Africa) , Lupin Limited (India) , Zydus Cadila (India)
Select User Access Type

Key Highlights of Report


Feb 2024 207 Pages 64 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Generic Drugs Quantitative research analysis
Global Generic Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Generic Drugs Market are by type [Simple Generic Drugs, Super Generic Drugs and Biosimilars], by end use application [Respiratory Products, Anti-Infective Drugs, Central Nervous System Drugs, Cardiovascular Products, Anti-Arthritis Drugs, Anti-Cancer Drugs and Other].
The Generic Drugs Market is gaining popularity and expected to see strong valuation by 2030.
  • Increasing Demand for Generic Drugs in Emerging Countries such as China and India
  • Cost-Benefit compared to the Branded Drugs
  • Large Number of Patent Expired Branded Drugs

Know More About Global Generic Drugs Report?

Have a Query? Click Here

Other Related Reports

Cold Rolled Steel Coil Comprehensive Study by Type (Civil Grade, Military Grade), Application (Automotive, Electronics, Aerospace & Defense, Power Industry, Construction), Steel Type (Cold Rolled Coi...
$ 3450
Underwater Acoustic Communication Comprehensive Study by Type (Shallow Water Range, Medium Water Range, Long Water Range, Full Ocean Range), Application (Environmental Monitoring, Pollution Monitorin...
$ 3750
Energy Storage Distributed Energy Resource Management System Comprehensive Study by Application (Residential, Commercial & Industrial, Utility-scale), Technology (Battery Energy Storage Systems (BESS...
$ 3800
Aircraft Tractor Comprehensive Study by Type (Conventional Tractors, Towbarless Tractors), Application (Airport, Civil Aviation, Military, Other) Players and Region - Global Market Outlook to 2026
$ 3500
Anti-inflammatory Drugs Comprehensive Study by Type (Aspirin,, Ibuprofen, Naproxen, COX-2 Inhibitors, Other), Application (Skin Rashes, Chronic Arthritis, Other), Treatment (Arthritis, Chronic obstru...
$ 3750
RTD Soy Milk Comprehensive Study by Type (Whole Soybeans Based, Full-Fat Soy Flour Based), Distribution Channels (Offline Channel, Online Channel), By Flavor (Soya Chocolate, Soya Honeydew, Soya Stra...
$ 3800